ABBOTINDIA
Abbott India Limited (ABBOTINDIA) Stock Analysis
Abbott India Limited is the Indian subsidiary of Abbott Laboratories, marketing pharmaceuticals, diagnostics, and nutritional products. Its portfolio includes trusted brands in gastroenterology, women's health, metabolic care, and consumer nutrition. The company sells largely through medical representatives and retail pharmacy networks across India. It is a large-cap listed pharma company with a long operating history in the country.
Healthcare › Drug Manufacturers - Specialty & Generic
₹26,000.00
-3.13% 1W | -13.40% 52W
Market Cap
55.2k CR
P/E Ratio
34.2
52W High
₹30655
52W Low
₹25135
Div. Yield
2.05%
Beta
0.1
50 DMA
₹26720.5
200 DMA
₹26767.4
Profit Margin
23.1%
Inst. Own.
6.8%
🔥 APPROACHING RESISTANCE
🔥 APPROACHING RESISTANCE
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,479 | 1,494 | 1,437 | 1,439 | 1,558 | 1,633 | 1,614 | 1,605 | 1,738 | 1,757 | 1,724 | 1,710 | 1,814 |
| Expenses | 1,124 | 1,113 | 1,049 | 1,109 | 1,167 | 1,194 | 1,178 | 1,176 | 1,293 | 1,255 | 1,261 | 1,229 | 1,291 |
| Operating Profit | 355 | 381 | 388 | 330 | 391 | 439 | 436 | 429 | 446 | 502 | 463 | 481 | 522 |
| OPM % | 24% | 25% | 27% | 23% | 25% | 27% | 27% | 27% | 26% | 29% | 27% | 28% | 29% |
| Other Income | 56 | 56 | 56 | 81 | 67 | 60 | 72 | 76 | 73 | 70 | 70 | 76 | 75 |
| Interest | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 4 | 6 | 8 | 5 | 6 | 6 |
| Depreciation | 17 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 19 | 19 | 19 | 19 | 20 |
| Profit before tax | 390 | 415 | 422 | 390 | 437 | 479 | 488 | 483 | 493 | 546 | 509 | 531 | 572 |
| Tax % | 26% | 25% | 26% | 26% | 25% | 25% | 26% | 24% | 26% | 24% | 26% | 26% | 25% |
| Net Profit | 290 | 313 | 311 | 287 | 328 | 359 | 361 | 367 | 366 | 415 | 376 | 395 | 429 |
| EPS in Rs | 136.59 | 147.27 | 146.35 | 135.09 | 154.36 | 168.76 | 169.78 | 172.73 | 172.18 | 195.43 | 176.93 | 185.86 | 201.66 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,289 | 2,614 | 2,903 | 3,298 | 3,679 | 4,093 | 4,310 | 4,919 | 5,349 | 5,849 | 6,409 | 6,929 | 7,004 |
| Expenses | 1,977 | 2,250 | 2,505 | 2,774 | 3,074 | 3,336 | 3,388 | 3,832 | 4,143 | 4,396 | 4,714 | 5,037 | 5,035 |
| Operating Profit | 312 | 365 | 398 | 525 | 605 | 757 | 922 | 1,088 | 1,206 | 1,453 | 1,695 | 1,892 | 1,969 |
| OPM % | 14% | 14% | 14% | 16% | 16% | 18% | 21% | 22% | 23% | 25% | 26% | 27% | 28% |
| Other Income | 48 | 50 | 57 | 117 | 113 | 114 | 81 | 77 | 154 | 248 | 275 | 288 | 291 |
| Interest | 0 | 3 | 2 | 4 | 2 | 9 | 18 | 19 | 16 | 12 | 11 | 25 | 25 |
| Depreciation | 15 | 14 | 16 | 16 | 17 | 60 | 58 | 66 | 70 | 71 | 72 | 76 | 76 |
| Profit before tax | 344 | 398 | 436 | 621 | 699 | 803 | 926 | 1,080 | 1,274 | 1,618 | 1,887 | 2,079 | 2,158 |
| Tax % | 34% | 36% | 37% | 35% | 36% | 26% | 25% | 26% | 25% | 26% | 25% | 25% | |
| Net Profit | 229 | 255 | 277 | 401 | 450 | 593 | 691 | 799 | 949 | 1,201 | 1,414 | 1,552 | 1,615 |
| EPS in Rs | 107.75 | 120.12 | 130.19 | 188.82 | 211.93 | 279.04 | 325.04 | 375.87 | 446.80 | 565.30 | 665.64 | 730.39 | 759.88 |
| Dividend Payout % | 29% | 29% | 31% | 29% | 31% | 90% | 85% | 73% | 73% | 73% | 71% | 90% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 9.0% | 10.0% | 10.0% |
| Profit CAGR | 18.0% | 17.0% | 20.0% |
Shareholding Pattern
Promoters74.99%
FIIs0.16%
DIIs9.18%
Public15.67%
Promoters74.99%
FIIs0.16%
DIIs9.11%
Public15.74%
Promoters74.99%
FIIs0.19%
DIIs9.00%
Public15.83%
Promoters74.99%
FIIs0.27%
DIIs8.93%
Public15.81%
Promoters74.99%
FIIs0.38%
DIIs8.77%
Public15.85%
Promoters74.99%
FIIs0.19%
DIIs8.61%
Public16.20%
Promoters74.99%
FIIs0.18%
DIIs8.91%
Public15.92%
Promoters74.99%
FIIs0.16%
DIIs8.91%
Public15.94%
Promoters74.99%
FIIs0.27%
DIIs8.93%
Public15.81%
Promoters74.99%
FIIs0.38%
DIIs8.77%
Public15.85%
ABBOTINDIA
Holdings Analysis
Key strengths & risk signals
68
Overall
79
Fundamental
58
Technical
Risks (3)
WEAK POSITION! Current price (26000.0) is below both moving averages.
WEAK YEAR! Stock declined 13.4% in the last year.
WEAK! Trading at 15.7% of 52W range - near yearly lows.
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH SENTIMENT! In last 30 days: 10 up days, 19 down days. Avg volume on up days: 11,416 vs down days: 6,516. Ratio: 1.75x
LOW VOLATILITY! Beta of 0.10 - stable stock, less market risk.
NEUTRAL! RSI at 43.9 - balanced momentum.
Fundamental & Technical Analysis
68Overall
79Fundamental
58Technical
Fundamental Breakdown
Growth Quality
21/30
Revenue CAGR: 9.0% (MODERATE, 8/15). Profit CAGR: 17.8% (VERY GOOD, 13/15).
Profit Margin
8/10
EXCELLENT EFFICIENCY! 23.1% profit margin - company keeps strong profits.
PEG Valuation
8/10
FAIRLY VALUED! PEG of 1.92 indicates reasonable valuation.
Dividend Yield
6/10
MODERATE DIVIDEND! 2.05% yield - some income benefit.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
16/20
LESS PUBLIC HOLDING! 16.05% public ownership - good institutional/promoter control.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
3/10
BEARISH TREND! 50-day average (26720.5) is below 200-day average (26767.4) - negative signal.
Price Position
2/10
WEAK POSITION! Current price (26000.0) is below both moving averages.
Trend Pattern
10/20
AT RESISTANCE! Stock is at key resistance level.
52W Performance
2/10
WEAK YEAR! Stock declined 13.4% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 10 up days, 19 down days. Avg volume on up days: 11,416 vs down days: 6,516. Ratio: 1.75x
RSI
3/5
NEUTRAL! RSI at 43.9 - balanced momentum.
52W Range
1/5
WEAK! Trading at 15.7% of 52W range - near yearly lows.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - -3.1% (1 week), 3.1% (1 month), -4.3% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.10 - stable stock, less market risk.
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBOTINDIA | ₹26,000.00 | 34.2 | 23.1% | 9.0% | 17.8% | -13.4% | 68 | APPROACHING RESISTANCE | +17.1% | +8.5% | +4.3% | +6.1% |
| GLAND | ₹3,061.80 | 44.7 | 16.8% | 21.3% | 9.6% | +63.8% | 83 | BREAKOUT | +47.1% | -13.6% | +19.6% | +3.3% |
| IPCALAB | ₹1,915.40 | 37.1 | 12.9% | 15.5% | 34.3% | +45.3% | 84 | BOUNCE FROM SUPPORT | +72.3% | +34.4% | +20.8% | +16.7% |
| ALKEM | ₹5,279.00 | 29.3 | 14.3% | 8.3% | 32.7% | -1.9% | 68 | HIT RESISTANCE | -21.7% | +119.9% | +10.9% | +3.8% |
| GLENMARK | ₹2,293.00 | 34.6 | 10.1% | 13.5% | 66.1% | +17.7% | 69 | BREAKDOWN | +929.6% | +60.2% | +28.5% | +4.6% |
| AJANTPHARM | ₹3,410.10 | 37.6 | 19.6% | 13.4% | 21.6% | +41.1% | 76 | BREAKDOWN | +30.9% | +25.3% | +24.8% | +14.4% |
| EMCURE | ₹1,833.50 | 34.4 | 10.4% | 15.4% | 20.2% | +34.8% | 81 | BREAKDOWN | +42.0% | +20.8% | +22.8% | +4.5% |
| WOCKPHARMA | ₹1,996.40 | 79.3 | 11.2% | 7.8% | – | +43.1% | 58 | CONSOLIDATION | -217.8% | -36.1% | +25.9% | -3.7% |
Data from TradeAlone · Updated daily
No news tagged for ABBOTINDIA yet.
